Sequential administration of anti-complement component C5 eculizumab and type-2 anti-CD20 obinutuzumab for the treatment of early antibody-mediated rejection after kidney transplantation: A proof of concept
Article in Clinical Immunology (May 2024)
The most recent citing publications are shown below. View all 471 publications that cite this research output on Dimensions.
Article in Clinical Immunology (May 2024)
Article in Kidney International Reports (May 2024)
Article in Transplantation Direct (May 2024)